Roy Galvin, Executive Vice President and Chief Commercial Officer of Haemonetics Corporation, filed a Form 4 on November 3, 2026, disclosing a disposition of 146 shares of common stock on October 30, 2026, related to RSU vesting tax obligations.

Key Highlights

  • Reporting person: Roy Galvin, EVP and Chief Commercial Officer of Haemonetics Corporation (NYSE:HAE)
  • Transaction: 146 shares of common stock disposed of (transaction code F) on October 30, 2026, at $119.65 per share
  • Purpose of disposal: Shares were withheld to satisfy tax obligations in connection with the vesting of previously reported restricted stock units (RSUs)
  • Post-transaction ownership: 39,805 shares of common stock beneficially owned directly following the reported transaction, including unvested RSUs previously reported
  • ESPP acquisition: The 39,805 share total includes 69 shares acquired under the Haemonetics Corporation 2007 Employee Stock Purchase Plan on October 31, 2026
  • Filing signed: Thomas V. Powers, attorney-in-fact for Mr. Galvin, signed the form on November 3, 2026

Haemonetics CCO Galvin Reports RSU Tax Withholding and ESPP Share Acquisition

According to the filing, Roy Galvin, who serves as Executive Vice President and Chief Commercial Officer of Haemonetics Corporation, reported a single non-derivative transaction involving the disposition of 146 shares of Haemonetics common stock on October 30, 2026. The transaction carried code "F," which the filing identifies as shares withheld to cover tax obligations arising from the vesting of certain restricted stock units previously reported.

The shares were disposed of at a price of $119.65 per share, the filing disclosed. Following the transaction, Galvin's direct beneficial ownership stood at 39,805 shares. The filing noted that this figure includes unvested RSUs previously reported, as well as 69 shares acquired by Galvin under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on October 31, 2026. No derivative securities transactions were reported in Table II of the form.

The form was filed on November 3, 2026, with the date of earliest transaction listed as October 30, 2026. Thomas V. Powers signed the form as attorney-in-fact for Mr. Galvin. No amendment date was indicated, suggesting this is an original filing rather than a revision to a prior submission.

What Was Disclosed

The filing reported the withholding of 146 Haemonetics common shares at $119.65 to cover taxes on vested RSUs, and noted that Galvin's resulting direct beneficial ownership totaled 39,805 shares, including 69 shares acquired via the company's employee stock purchase plan on October 31, 2026.